Galleri Cancer Test: Study Disappoints, Stock Plummets 50%
Grail’s Galleri Cancer Screening Test Shows Limited Benefit in Landmark Study, Stock Plummets Shares of Grail, the biotech firm pioneering multi-cancer early detection (MCED) tests, experienced a dramatic 50% decline following the release of initial data from a pivotal clinical trial of its Galleri blood test. While the study did not achieve statistical significance in … Read more